Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Ibrutinib has transformed chronic lymphocytic leukemia (CLL) treatment since 2014.
• Real-world data on ibrutinib use and outcomes in Canada are crucial.

Purpose of the Study:

• To analyze ibrutinib utilization patterns in British Columbia (BC).
• To evaluate real-world survival outcomes and adverse events (AEs) in CLL patients treated with ibrutinib.
• To identify factors influencing treatment discontinuation.

Main Methods:

• Retrospective analysis of 370 CLL patients treated with ibrutinib (2014-2018) in BC.
• Data collection on patient demographics, treatment lines (first-line vs. relapsed/refractory), dose modifications, AEs, and survival.
• Kaplan-Meier survival analysis for overall survival (OS) and event-free survival (EFS).

Main Results:

• 35% of patients discontinued ibrutinib, mainly due to adverse events (AEs), not disease progression.
• 87% of patients experienced at least one AE during treatment.
• Excellent 2-year OS (83.9%) and EFS (76.1%) were observed.
• Patients discontinuing ibrutinib had significantly shorter median OS (32.5 months) and EFS (3.8 months).

Conclusions:

• Ibrutinib demonstrates high efficacy and survival rates in real-world CLL treatment in BC.
• Managing ibrutinib-related toxicities is essential for sustained patient benefit.
• Minimizing adverse events is critical to prevent treatment discontinuation and improve long-term outcomes.